United States Biotechnology & Medical Research

Epizyme Inc (EPZM)

Track

Ticker: EPZM Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Epizyme Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 11 Apr 2022
Value US$1,058,460.84 | Price 454.82 | Shares 28,614 (+37.6%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2022-04-13 2022-04-11 PlS Planned sale
Kutok Jeffery

Chief Scientific Officer

Officer
28,614 +37.6%
454.82
US$1,058,461 		28,614 +37.6% 454.82 US$1,058,461
2022-02-09 2022-02-07 PlS Planned sale
1.3
Agarwal Shefali

See Remarks

Officer
23,886 -19.8%
134.83
US$1,690,664 		23,886 -19.8% 134.83 US$1,690,664
2022-02-09 2022-02-07 PlS Planned sale
Beaulieu Joseph

Corporate Controller

Officer
67,145 -26.8%
67.17
US$3,165,879 		67,145 -26.8% 67.17 US$3,165,879
2022-02-04 2022-02-02 PlS Planned sale
1.3
Agarwal Shefali

See Remarks

Officer
2,639 -1.6%
1.37
US$3,615 		2,639 -1.6% 1.37 US$3,615
2022-02-04 2022-02-02 PlS Planned sale
Beaulieu Joseph

Corporate Controller

Officer
687 -2.3%
1.37
US$941 		687 -2.3% 1.37 US$941
2022-02-04 2022-02-02 PlS Planned sale
Kutok Jeffery

Chief Scientific Officer

Officer
2,556 -2.6%
1.37
US$3,502 		2,556 -2.6% 1.37 US$3,502
2022-02-01 2022-01-31 B Purchase
1.7
Legorreta Pablo G.
Non-Executive Director Large shareholder
22,666,667 +247.3%
1.50
US$34,000,000 		22,666,667 +247.3% 1.50 US$34,000,000
2022-01-28 2022-01-26 PlS Planned sale
1.3
Agarwal Shefali

See Remarks

Officer
2,922 -1.8%
2.02
US$5,902 		2,922 -1.8% 2.02 US$5,902
2021-12-07 2021-12-06 PlS Planned sale
1.3
Agarwal Shefali

See Remarks

Officer
1,780 -1.1%
2.93
US$5,215 		1,780 -1.1% 2.93 US$5,215
2021-03-29 2021-03-26 B Purchase
4.0
MOTT DAVID M
Non-Executive Director
217 +0.1%
7.80
US$1,693 		217 +0.1% 7.80 US$1,693
2021-03-29 2021-03-26 B Purchase
4.0
MOTT DAVID M
Non-Executive Director
34,269 +29.4%
7.97
US$273,124 		34,269 +29.4% 7.97 US$273,124
2021-03-29 2021-03-25 PlS Planned sale
3.6
Bazemore Robert B

President & CEO

Executive Director
10,328 -3.1%
7.85
US$81,075 		10,328 -3.1% 7.85 US$81,075
2021-03-29 2021-03-25 B Purchase
4.0
MOTT DAVID M
Non-Executive Director
28,231 +32.0%
7.98
US$225,283 		28,231 +32.0% 7.98 US$225,283
2021-02-05 2021-02-04 PlS Planned sale
Beaulieu Joseph

Corporate Controller

Officer
227 -1.7%
11.21
US$2,545 		227 -1.7% 11.21 US$2,545
2021-02-05 2021-02-04 PlS Planned sale
Ros Matthew

See Remarks

Officer
894 -1.1%
11.21
US$10,022 		894 -1.1% 11.21 US$10,022
2021-02-05 2021-02-04 PlS Planned sale
1.3
Agarwal Shefali

Chief Medical Officer

Officer
969 -0.9%
11.21
US$10,862 		969 -0.9% 11.21 US$10,862
2021-02-05 2021-02-04 PlS Planned sale
TOMBESI PAOLO

Chief Financial Officer

Officer
1,021 -1.9%
11.21
US$11,445 		1,021 -1.9% 11.21 US$11,445
2021-02-05 2021-02-04 PlS Planned sale
3.6
Bazemore Robert B

President & CEO

Executive Director
3,890 -1.2%
11.21
US$43,607 		3,890 -1.2% 11.21 US$43,607
2021-02-05 2021-02-04 PlS Planned sale
1.5
Vakiener Victoria

Chief Commercial Officer

Officer
817 -1.5%
11.21
US$9,159 		817 -1.5% 11.21 US$9,159
2021-01-27 2021-01-25 PlS Planned sale
Ros Matthew

See Remarks

Officer
2,872 -4.9%
11.41
US$32,770 		2,872 -4.9% 11.41 US$32,770
2021-01-27 2021-01-25 PlS Planned sale
3.6
Bazemore Robert B

President & CEO

Executive Director
6,069 -2.4%
11.41
US$69,247 		6,069 -2.4% 11.41 US$69,247
2021-01-27 2021-01-25 PlS Planned sale
1.3
Agarwal Shefali

Chief Medical Officer

Officer
2,872 -3.7%
11.41
US$32,770 		2,872 -3.7% 11.41 US$32,770
2021-01-27 2021-01-25 PlS Planned sale
1.5
Vakiener Victoria

Chief Commercial Officer

Officer
599 -2.1%
11.41
US$6,835 		599 -2.1% 11.41 US$6,835
2020-12-07 2020-12-03 PlS Planned sale
1.3
Agarwal Shefali

Chief Medical Officer

Officer
2,522 -3.2%
13.54
US$34,148 		2,522 -3.2% 13.54 US$34,148
2020-11-13 2020-11-11 B Purchase
1.3
GOLDFISCHER CARL
Non-Executive Director
5,000 +inf%
12.07
US$60,350 		5,000 +inf% 12.07 US$60,350
2020-09-03 2020-09-02 PlS Planned sale
Beaulieu Joseph

Corporate Controller

Officer
543 -8.4%
12.88
US$6,994 		543 -8.4% 12.88 US$6,994
2020-06-26 2020-06-26 B Purchase
4.0
MOTT DAVID M
Non-Executive Director
62,019 +301.3%
16.03
US$994,165 		62,019 +301.3% 16.03 US$994,165
2020-06-22 2020-06-18 PlS Planned sale
Ros Matthew

See Remarks

Officer
68,651 -57.0%
21.65
US$1,486,294 		68,651 -57.0% 21.65 US$1,486,294
2020-06-22 2020-06-18 PlS Planned sale
Ros Matthew

See Remarks

Officer
2,289 -4.2%
22.00
US$50,358 		2,289 -4.2% 22.00 US$50,358
2020-06-22 2020-06-18 PlS Planned sale
Ros Matthew

See Remarks

Officer
41,063 -44.2%
20.50
US$841,792 		41,063 -44.2% 20.50 US$841,792
2020-06-22 2020-06-18 S Sale
3.6
Bazemore Robert B

President & CEO

Executive Director
10,000 -3.9%
22.00
US$220,000 		10,000 -3.9% 22.00 US$220,000
2020-06-22 2020-06-18 S Sale
3.6
Bazemore Robert B

President & CEO

Executive Director
10,000 -3.8%
22.00
US$220,000 		10,000 -3.8% 22.00 US$220,000
2020-03-26 2020-03-25 PlS Planned sale
Beaulieu Joseph

Corporate Controller

Officer
212 -4.1%
15.28
US$3,239 		212 -4.1% 15.28 US$3,239
2020-03-26 2020-03-25 PlS Planned sale
1.3
Agarwal Shefali

Chief Medical Officer

Officer
1,243 -1.7%
15.28
US$18,993 		1,243 -1.7% 15.28 US$18,993
2020-03-26 2020-03-25 PlS Planned sale
Ros Matthew

See Remarks

Officer
1,243 -2.3%
15.28
US$18,993 		1,243 -2.3% 15.28 US$18,993
2020-03-26 2020-03-25 PlS Planned sale
TOMBESI PAOLO

Chief Financial Officer

Officer
1,243 -7.5%
15.28
US$18,993 		1,243 -7.5% 15.28 US$18,993
2020-03-26 2020-03-25 PlS Planned sale
3.6
Bazemore Robert B

President & CEO

Executive Director
3,285 -1.3%
15.28
US$50,195 		3,285 -1.3% 15.28 US$50,195
2020-03-05 2020-03-03 PlS Planned sale
Beaulieu Joseph

Corporate Controller

Officer
996 -21.6%
22.18
US$22,091 		996 -21.6% 22.18 US$22,091
2020-01-27 2020-01-27 PlS Planned sale
3.6
Bazemore Robert B

President & CEO

Executive Director
6,074 -6.7%
20.44
US$124,153 		6,074 -6.7% 20.44 US$124,153
2020-01-27 2020-01-27 PlS Planned sale
1.3
Agarwal Shefali

Chief Medical Officer
2,630 -4.3%
20.44
US$53,757 		2,630 -4.3% 20.44 US$53,757
2020-01-27 2020-01-24 PlS Planned sale
3.6
Bazemore Robert B

President & CEO

Executive Director
3,002 -3.2%
24.62
US$73,909 		3,002 -3.2% 24.62 US$73,909
2020-01-27 2020-01-24 PlS Planned sale
Ros Matthew

See Remarks
1,847 -4.2%
24.64
US$45,510 		1,847 -4.2% 24.64 US$45,510
2020-01-27 2020-01-24 PlS Planned sale
Beaulieu Joseph

Corporate Controller
330 -24.1%
24.63
US$8,128 		330 -24.1% 24.63 US$8,128
2020-01-27 2020-01-24 PlS Planned sale
1.3
Agarwal Shefali

Chief Medical Officer
1,843 -2.9%
24.64
US$45,412 		1,843 -2.9% 24.64 US$45,412
2020-09-03 2019-09-03 PlS Planned sale
Beaulieu Joseph

Corporate Controller

Officer
971 -13.0%
12.77
US$12,400 		971 -13.0% 12.77 US$12,400
2019-06-28 2019-06-27 S Sale
4.0
MOTT DAVID M
52,473 -100.0%
12.43
US$652,134 		52,473 -100.0% 12.43 US$652,134
2019-06-26 2019-06-26 S Sale
4.0
MOTT DAVID M
52,472 -50.0%
12.85
US$674,176 		52,472 -50.0% 12.85 US$674,176
2019-06-26 2019-06-25 S Sale
4.0
MOTT DAVID M
52,472 -33.3%
13.31
US$698,649 		52,472 -33.3% 13.31 US$698,649
2019-06-17 2019-06-14 PlS Planned sale
1.3
Agarwal Shefali

Chief Medical Officer
1,195 -3.2%
11.97
US$14,304 		1,195 -3.2% 11.97 US$14,304
2019-06-14 2019-06-13 PlS Planned sale
3.6
Bazemore Robert B

President & CEO

Executive Director
2,074 -2.4%
12.10
US$25,095 		2,074 -2.4% 12.10 US$25,095
2019-06-14 2019-06-13 PlS Planned sale
Ros Matthew

See Remarks
1,185 -2.9%
12.10
US$14,338 		1,185 -2.9% 12.10 US$14,338
2019-06-14 2019-06-13 PlS Planned sale
Beaulieu Joseph

Corporate Controller
203 -29.0%
12.10
US$2,456 		203 -29.0% 12.10 US$2,456
2018-10-05 2018-10-05 B Purchase MOTT DAVID M Non-Executive Director
416,667 +6.9%
9.00
US$3,750,003 		416,667 +6.9% 9.00 US$3,750,003
2018-02-06 2018-02-05 S Sale Ros Matthew

Chief Operating Officer

Officer
519 -16.6%
17.20
US$8,927 		519 -16.6% 17.20 US$8,927
2018-02-06 2018-02-05 S Sale Ros Matthew

Chief Operating Officer

Officer
71,745 -95.8%
16.63
US$1,192,768 		71,745 -95.8% 16.63 US$1,192,768
2017-10-25 2017-10-24 S Sale Ho Peter Tai-Ching

Chief Development Officer
15,000 -64.9%
16.44
US$246,591 		15,000 -64.9% 16.44 US$246,591
2017-09-26 2017-09-25 S Sale Ho Peter Tai-Ching

Chief Development Officer
15,000 -64.9%
16.81
US$252,076 		15,000 -64.9% 16.81 US$252,076
2017-09-18 2017-09-18 B Purchase MOTT DAVID M
200,000 +3.4%
15.25
US$3,050,000 		200,000 +3.4% 15.25 US$3,050,000
2017-08-28 2017-08-24 S Sale Ho Peter Tai-Ching

Chief Development Officer
15,000 -67.5%
15.68
US$235,266 		15,000 -67.5% 15.68 US$235,266
2017-07-26 2017-07-24 S Sale Ho Peter Tai-Ching

Chief Development Officer

Officer
15,000 -67.5%
13.44
US$201,572 		15,000 -67.5% 13.44 US$201,572
2017-07-05 2017-06-30 PlS Planned sale Singer Andrew E.

EVP & CFO

Officer
3,024 -6.9%
15.50
US$46,872 		3,024 -6.9% 15.50 US$46,872
2017-06-27 2017-06-26 S Sale Ho Peter Tai-Ching

Chief Development Officer
15,000 -67.5%
14.87
US$223,114 		15,000 -67.5% 14.87 US$223,114
2017-06-07 2017-06-06 S Sale Copeland Robert A

President of Research and CSO
2,500 -7.3%
13.45
US$33,625 		2,500 -7.3% 13.45 US$33,625
2017-05-26 2017-05-25 S Sale Ho Peter Tai-Ching

Chief Development Officer

Officer
15,000 -67.5%
16.11
US$241,664 		15,000 -67.5% 16.11 US$241,664
2017-05-03 2017-05-02 S Sale Copeland Robert A

President of Research and CSO

Officer
5,000 -13.7%
17.44
US$87,212 		5,000 -13.7% 17.44 US$87,212
2017-04-05 2017-04-04 S Sale Copeland Robert A

President of Research and CSO
2,500 -7.3%
16.36
US$40,896 		2,500 -7.3% 16.36 US$40,896
2017-04-05 2017-04-04 S Sale Copeland Robert A

President of Research and CSO
2,500 -6.8%
16.36
US$40,909 		2,500 -6.8% 16.36 US$40,909
2017-04-03 2017-03-31 PlS Planned sale Singer Andrew E.

EVP & CFO
2,013 -5.3%
17.09
US$34,394 		2,013 -5.3% 17.09 US$34,394
2017-01-10 2017-01-09 PlS Planned sale Singer Andrew E.

EVP & CFO
1,013 -3.0%
12.04
US$12,194 		1,013 -3.0% 12.04 US$12,194
2016-12-12 2016-12-09 PlS Planned sale Singer Andrew E.

EVP & CFO

Officer
1,013 -3.1%
11.03
US$11,172 		1,013 -3.1% 11.03 US$11,172
2016-12-12 2016-12-08 S Sale Ho Peter Tai-Ching

Chief Development Officer

Officer
200 -3.5%
10.89
US$2,179 		200 -3.5% 10.89 US$2,179
2016-11-10 2016-11-09 PlS Planned sale Singer Andrew E.

EVP & CFO

Officer
1,013 -3.2%
10.40
US$10,535 		1,013 -3.2% 10.40 US$10,535
2016-10-12 2016-10-10 PlS Planned sale Singer Andrew E.

EVP & CFO

Officer
1,013 -3.4%
9.72
US$9,848 		1,013 -3.4% 9.72 US$9,848
2016-09-12 2016-09-09 PlS Planned sale Singer Andrew E.

EVP & CFO

Officer
1,013 -3.6%
7.55
US$7,651 		1,013 -3.6% 7.55 US$7,651
2016-08-10 2016-08-09 PlS Planned sale Singer Andrew E.

EVP & CFO

Officer
1,013 -3.7%
9.05
US$9,166 		1,013 -3.7% 9.05 US$9,166
Explore more

More insider trading research around Epizyme Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America